Correspondence: Dr C Daly, Department of Oncology, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. E-mail: christopher.daly@regeneron.com The epidermal growth factor receptor is a clinically validated target in head and neck squamous cell carcinoma , where EGFR-blocking antibodies are approved for first-line treatment.
http://ift.tt/28YO6oL
No comments:
Post a Comment